Patents by Inventor Daniel Sommermeyer
Daniel Sommermeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12780897Abstract: The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).Type: GrantFiled: August 25, 2023Date of Patent: November 3, 2026Assignee: Fred Hutchinson Cancer CenterInventors: Marie Bleakley, Robson Dossa, Daniel Sommermeyer
-
Publication number: 20260327287Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: March 4, 2026Publication date: October 22, 2026Inventors: Jasdeep Mann, Christian Ellinger, Daniel Sommermeyer, Benjamin Boyerinas
-
Patent number: 12590136Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: GrantFiled: May 7, 2020Date of Patent: March 31, 2026Assignees: Regeneron Pharmaceuticals, Inc., MEDIGENE IMMUNOTHERAPIES GMBHInventors: Jasdeep Mann, Christian Ellinger, Daniel Sommermeyer, Benjamin Boyerinas
-
Publication number: 20250346648Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: ApplicationFiled: May 23, 2025Publication date: November 13, 2025Inventors: Christian Ellinger, Daniel Sommermeyer, Geoffrey Parsons, Jasdeep Mann
-
Patent number: 12344654Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: GrantFiled: March 27, 2020Date of Patent: July 1, 2025Assignees: MEDIGENE IMMUNOTHERAPIES GMBH, Regeneron Pharmaceuticals, Inc.Inventors: Christian Ellinger, Daniel Sommermeyer, Geoffrey Parsons, Jasdeep Mann
-
Patent number: 12195515Abstract: The present invention covers an isolated T cell receptor (TCR) specific for one allelic variant of minor histocompatibility antigen 1 (HA-1), in particular the allelic variant HA-1H. An isolated polypeptide comprising a functional portion of the TCR is also described. Moreover, a multivalent TCR complex, nucleic acid molecules, vectors, cells, antibodies as well as medical uses that relate to the TCR are defined.Type: GrantFiled: August 6, 2019Date of Patent: January 14, 2025Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian Ellinger, Daniel Sommermeyer, Aline Bracher
-
Patent number: 12173318Abstract: The present invention describes methods and uses of antibodies targeting the C?1 or the C?2 chain of a TCR, in particular an anti-C?1 antibody, for enrichment of T cells expressing a desired antigen-specific recombinant T cell receptor (TCR).Type: GrantFiled: August 17, 2021Date of Patent: December 24, 2024Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Daniel Sommermeyer, Slavoljub Milosevic, Anna Schleicher
-
Publication number: 20240279307Abstract: The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).Type: ApplicationFiled: August 25, 2023Publication date: August 22, 2024Inventors: Marie BLEAKLEY, Robson DOSSA, Daniel SOMMERMEYER
-
Publication number: 20240277762Abstract: The present invention relates to the combination of a T cell receptor (TCR) specific for the FRAME peptide SLLQH-LIGL and a chimeric co-stimulatory receptor comprising an extracellular domain derived from PD-1(CD279) and an intracellular domain derived from 4-1BB (CD137). In particular, the invention refers to a cell comprising said TCR and chimeric co-stimulatory protein. Further the invention refers to a nucleic acid encoding the TCR and the co-stimulatory receptor, a corresponding vector and a corresponding nucleic acid composition. Moreover, the invention relates to the according pharmaceutical composition. Accordingly the invention also relates to the cell and the nucleic acid constructs for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: ApplicationFiled: May 6, 2022Publication date: August 22, 2024Inventors: Nadja SAILER, Melanie SALVERMOSER, Daniel SOMMERMEYER, Susanne WILDE, Ina FETZER, Maja BÜRDEK
-
Publication number: 20230287345Abstract: The present invention describes methods and uses of antibodies targeting the C?1 or the C?2 chain of a TCR, in particular an anti-C?1 antibody, for enrichment of T cells expressing a desired antigen-specific recombinant T cell receptor (TCR).Type: ApplicationFiled: August 17, 2021Publication date: September 14, 2023Inventors: Daniel SOMMERMEYER, Slavoljub MILOSEVIC, Anna SCHLEICHER
-
Publication number: 20230159612Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for MAGE-A4 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: ApplicationFiled: March 27, 2020Publication date: May 25, 2023Inventors: Christian ELLINGER, Daniel SOMMERMEYER, Geoffrey PARSONS, Jasdeep MANN
-
Publication number: 20230044580Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.Type: ApplicationFiled: May 7, 2020Publication date: February 9, 2023Applicants: 2SEVENTY BIO, INC., MEDIGENE IMMUNOTHERAPIES GMBHInventors: JASDEEP MANN, CHRISTIAN ELLINGER, DANIEL SOMMERMEYER, BENJAMIN BOYERINAS
-
Publication number: 20220251235Abstract: The present invention relates to an isolated T cell receptor (TCR) specific for a MAGEA10-derived peptide and to a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.Type: ApplicationFiled: July 8, 2020Publication date: August 11, 2022Inventors: Daniel SOMMERMEYER, Christian ELLINGER, Aline BRACHER, Christiane MUMMERT, Laura PRASSMAYER, Raphaela PUTZHAMMER, Alexandra SEMMELMANN
-
Publication number: 20210300987Abstract: The present invention covers an isolated T cell receptor (TCR) specific for one allelic variant of minor histocompatibility antigen 1 (HA-1), in particular the allelic variant HA-1H. An isolated polypeptide comprising a functional portion of the TCR is also described. Moreover, a multivalent TCR complex, nucleic acid molecules, vectors, cells, antibodies as well as medical uses that relate to the TCR are defined.Type: ApplicationFiled: August 6, 2019Publication date: September 30, 2021Inventors: Christian ELLINGER, Daniel SOMMERMEYER, Aline BRACHER
-
Publication number: 20200231649Abstract: The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).Type: ApplicationFiled: December 2, 2019Publication date: July 23, 2020Inventors: Marie BLEAKLEY, Robson DOSSA, Daniel SOMMERMEYER
-
Patent number: 10538574Abstract: The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).Type: GrantFiled: March 22, 2019Date of Patent: January 21, 2020Assignee: FRED HUTCHINSON CANCER RESEARCH CENTERInventors: Marie Bleakley, Robson Dossa, Daniel Sommermeyer
-
Publication number: 20190211076Abstract: The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).Type: ApplicationFiled: March 22, 2019Publication date: July 11, 2019Inventors: Marie Bleakley, Robson Dossa, Daniel Sommermeyer